Jacobson Pharma Corporation Limited, through its subsidiaries, produces, markets, and sells generic drugs and branded healthcare products in Hong Kong, Mainland China, Macau, Singapore, and internationally. The company offers generic drugs for various therapeutic categories, including the respiratory, cardiovascular, central nervous system, gastrointestinal, genito-urinary, musculoskeletal, endocrine and metabolic, dermatological, anti-allergics, scar treatment, oral anti-diabetics, and anti-infective, as well as arsenic trioxide oral solutions, rosuvastatin tablets, and atorvastatin tablets. It also provides branded medicines; health and wellness products; and proprietary Chinese medicines, such as Po Chai pills, Ho Chai Kung Tji Thung San, Tong Tai Chung Woodlok oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling oil, Contractubex, Doan's Ointment, and Col-gan tablets. In addition, it engages in the trading of medical supplies; procurement of packaging materials; sale of healthcare and herbal products; research and development; and property holding activities. Jacobson Pharma Corporation Limited sells its products to hospitals and clinics, and registered pharmacies, as well as to doctors in private and retail outlets, and trading companies. The company was incorporated in 2016 and is headquartered in Kwun Tong, Hong Kong. Jacobson Pharma Corporation Limited is a subsidiary of Kingshill Development Limited.
Jacobson Pharma Dividend Announcement
• Jacobson Pharma announced a annually dividend of HK$0.04 per ordinary share which will be made payable on 2025-04-02. Ex dividend date: 2025-02-25
• Jacobson Pharma's trailing twelve-month (TTM) dividend yield is 6.63%
• Jacobson Pharma's payout ratio for the trailing twelve months (TTM) is 39.21%
Jacobson Pharma Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2025-02-25 | HK$0.04 | annually | 2025-04-02 |
2024-09-03 | HK$0.03 | annually | 2024-10-04 |
2023-12-18 | HK$0.03 | annually | 2024-01-10 |
2023-08-15 | HK$0.02 | annually | 2023-09-01 |
2022-12-08 | HK$0.03 | annually | 2022-12-29 |
2022-10-03 | HK$0.03 | annually | 2022-10-18 |
2021-12-09 | HK$0.01 | annually | 2021-12-23 |
2021-10-05 | HK$0.01 | annually | 2021-10-19 |
2020-12-17 | HK$0.01 | annually | 2021-01-06 |
2020-09-25 | HK$0.03 | annually | 2020-10-13 |
2019-12-06 | HK$0.02 | annually | 2019-12-23 |
2019-08-30 | HK$0.03 | annually | 2019-09-12 |
2018-12-05 | HK$0.01 | annually | 2018-12-21 |
2018-09-12 | HK$0.03 | annually | 2018-09-27 |
2017-11-27 | HK$0.01 | annually | 2017-12-19 |
2017-09-12 | HK$0.01 | annually | 2017-09-28 |
2017-01-09 | HK$0.01 | annually | 2017-01-20 |
Jacobson Pharma Dividend per year
Jacobson Pharma Dividend growth
Jacobson Pharma Dividend Yield
Jacobson Pharma current trailing twelve-month (TTM) dividend yield is 6.63%. Interested in purchasing Jacobson Pharma stock? Use our calculator to estimate your expected dividend yield:
Jacobson Pharma Financial Ratios
Jacobson Pharma Dividend FAQ
Other factors to consider when evaluating Jacobson Pharma as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Jacobson Pharma stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Jacobson Pharma's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Jacobson Pharma publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Jacobson Pharma distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Jacobson Pharma are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Jacobson Pharma sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Jacobson Pharma distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Jacobson Pharma declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Jacobson Pharma's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Jacobson Pharma's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.